National HealthCare Corporation

Fundamentals8.0
Price Action6.0
News Sentiment7.0
AI Rating
7.0

Key Drivers

  • Strong FCF
  • High SG&A
  • Quarter weakness

AI
AI Summary

7.0

NHC has shifted from a dividend/defensive story to a cash‑flow–driven operational growth thesis—16% revenue growth and strong annual FCF mean valuation now hinges on execution (cost control and margin stability). Monitor the next two quarters for margin re‑expansion and consistent quarterly FCF (or else the current multiple and $155–158 support risk re‑rating).

CashFlow
MarginRisk
Execution‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

8.0

Key Financial Insights:

  • Strong FCF
  • High SG&A
  • Quarter weakness

NHC shows solid balance-sheet strength and strong annual cash generation with attractive ROIC, but high operating costs and recent quarterly margin compression are key risks.

StrongCash
MarginRisk

Price Behavior

6.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Below 21‑day avg
  • Limited momentum
  • Resistance near $172.83

Over the last month NHC is neutral-to-slightly-bearish: last close $158.81 sits modestly below the last month average $161.90 with only ~+0.6% net change, support around $155–$158 and clear resistance at $172.83 amid moderate ~10–11% intraperiod volatility.

slightBear
rangeBound
Support Level: $155–$158
Resistance Level: $172.83

~10–11% high/low range over last month, signaling moderate intraperiod volatility

Sentiment & News

7.0

Key News Insights:

  • Strong revenue growth
  • Same‑facility improvement
  • Minor investor trim

NHC posted 16.1% revenue growth to $1.518B in 2025 driven by same‑facility gains, while Dimensional's 0.4% stake trim signals only a minor institutional adjustment.

NHC_upside
Institutional_shift

The results reinforce NHC's operational momentum and should support the stock's fundamental case, with the small institutional sell‑down unlikely to materially alter investor confidence